NASDAQ:TXMD TherapeuticsMD Q3 2026 Earnings Results & Report $1.87 +0.05 (+2.75%) As of 11/13/2026 04:00 PM Eastern TherapeuticsMD beat analyst earnings expectations but missed on revenue in its Q3 2026 results, released November 13, 2026. The company reported EPS of $0.04 versus the -$6.1250 consensus estimate, while revenue of $1.26 million fell short of the $19.77 million estimate by $18.51 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 13, 2026TimeAfter Market ClosesConference Call7:00 AM ET TherapeuticsMD EPS ResultsActual EPS$0.04Consensus EPS -$6.1250Beat/MissBeat by +$6.1650One Year Ago EPSN/AEPS Beat Rate4 of last 5 quartersTherapeuticsMD Revenue ResultsActual Revenue$1.26 millionExpected Revenue$19.77 millionBeat/MissMissed by -$18.51 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) TherapeuticsMD Q3 2026 Earnings FAQ Did TherapeuticsMD beat earnings estimates for Q3 2026? TherapeuticsMD (NASDAQ:TXMD) reported earnings of $0.04 per share for Q3 2026, beating the consensus estimate of -$6.1250. The report was announced on Friday, November 13, 2026. What was TherapeuticsMD's revenue for Q3 2026? TherapeuticsMD reported revenue of $1.26 million for Q3 2026, against a consensus estimate of $19.77 million. TherapeuticsMD Earnings HeadlinesTherapeuticsMD Announces Third Quarter 2026 Financial ResultsNovember 13 at 4:05 PM | businesswire.comTherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gainsJune 5, 2026 | marketwatch.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | Porter & Company (Ad)TherapeuticsMD Reports Quarterly Profit, Evaluates Strategic AlternativesMay 12, 2026 | tipranks.comTherapeuticsMD Announces First Quarter 2026 Financial ResultsMay 12, 2026 | businesswire.comTherapeuticsMD Inc. stock outperforms competitors on strong trading dayApril 6, 2026 | marketwatch.comSee More TherapeuticsMD Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TherapeuticsMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TherapeuticsMD and other key companies, straight to your email. Email Address About TherapeuticsMDTherapeuticsMD (NASDAQ:TXMD) was a U.S. women’s health pharmaceutical company that developed and commercialized prescription products addressing contraception and symptoms associated with menopause. Its business was primarily focused on the U.S. market. The company’s products included ANNOVERA, a reusable contraceptive vaginal system; IMVEXXY, estradiol vaginal inserts prescribed for certain menopausal symptoms; and BIJUVA, an oral estradiol and progesterone treatment for moderate-to-severe vasomotor symptoms associated with menopause in eligible women. In 2023, TherapeuticsMD sold substantially all of its assets, including rights to these products, to Mayne Pharma. The products and commercial activities described here reflect TherapeuticsMD’s historical business.View TherapeuticsMD ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
